pemetrexed,carboplatin,paclitaxel,vinorelbine,nivolumab,cisplatin,docetaxel,gemcitabine,ipilimumab,pembrolizumab
merck,bms
[]
 nobody disagrees on principle though it is more than reasonable to identify the patients who benefit the most. the one size fits all is totally unacceptable in the era of precision medicine and oncology imho
Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own